mTORC1 Inactivation Prevents and Eradicates Acute Lymphoblastic T-Cell Leukemia

Blood ◽  
2013 ◽  
Vol 122 (21) ◽  
pp. 1211-1211
Author(s):  
Takayuki Hoshii ◽  
Atsuo Kasada ◽  
Tomoki Hatakeyama ◽  
Masashi Ohtani ◽  
Yuko Tadokoro ◽  
...  

Abstract mTOR is a serine/threonine kinase that has a central role in the regulation of cell growth and cell metabolism and forms two functionally different complexes, named mTORC1 and mTORC2. Despite the effectiveness of rapamycin, an allosteric mTOR inhibitor, in immunosuppression, the precise roles of mTORCs in T-cell development remain unclear. Here we show that mTORC1 plays a critical role in the earliest development of T-cell progenitors. To understand the physiological role of mTORC1 in T-cell development, we evaluated the effects of mTORC1 inhibition by rapamycin treatment or the genetic deletion of the Raptor gene, an essential component of mTORC1. Raptor deficiency dramatically inhibited the development of CD4/CD8 double-positive (DP) cells. Rapamycin treatment produced similar defects, but to a lesser extent. Deficiency of Raptor, but not Rictor, a mTORC2 component, resulted in abnormality of cell cycle of early T-cell progenitors, associated with instability of the Cyclin D3/CDK6 complex, indicating that mTORC1 and 2 control T-cell development in different manners. When we treated T-cells with a proteasome inhibitor, MG-132, in vitro, the reduction of Cyclin D3 and CDK6 by mTORC1 inactivation was reversed. These data suggest that mTORC1 activity may control the Cyclin D3/CDK6 complex via post-transcriptional mechanisms. In a model of myeloproliferative neoplasm (MPN) and T-cell leukemia (T-ALL) evoked by Kras activation, rapamycin treatment prevents development of T-ALL, but not MPN. After the onset of T-ALL, rapamycin-insensitive Notch-driven T-ALL cells survived in vivo. Raptor deficiency dramatically inhibited proliferation of oncogenic Kras–expressing T-cell progenitors and prevents the development of T-ALL, but not MPN. In contrast to T-cell progenitors, cell cycle of myeloid progenitors was not affected by mTORC1 inactivation. Phosphorylation of p70S6K and 4E-BP1, direct substrates of mTORC1, was apparently decreased in Raptor-deficient myeloid cells. Interestingly, consistent with hypo-phosphorylation of p70S6K and 4E-BP1, rates of newly synthesized protein were significantly reduced in cycling Raptor-deficient progenitors. These data indicate that the impact of mTORC1 deficiency on cell cycle status varies substantially depending on the cell context. In addition, we evaluated the effect of hyperactivation of mTORC1 by Tsc1 deletion on the behavior of T-ALL. Tsc1 deficiency shortened survival, and promoted the cell proliferation, as well as the dissemination of active Notch-driven T-ALL cells in non-hematopoietic tissues. However, strikingly, Raptor deficiency resulted in efficient leukemia eradication. Thus, understanding the cell-context-dependent role of mTORC1 illustrates the potential importance of mTOR signals as therapeutic targets. Disclosures: No relevant conflicts of interest to declare.

Blood ◽  
2010 ◽  
Vol 116 (21) ◽  
pp. 706-706
Author(s):  
Cyrus Khandanpour ◽  
Tarik Moroy

Abstract Abstract 706 Gfi1 is a transcriptional repressor with important roles in the development and malignant transformation of T-cells. Gfi1 deficient mice have reduced thymic cellularity and show a partial block of differentiation of the double negative (CD4/CD8) pre-T cells into more mature stages. It is also known that Gfi1 is preferably selected as a proviral insertion site in retrovirally induced T-cell tumors in mice, which led to the concept that high-level expression of Gfi1 may be required or may drive T-cell leukemogenesis. This was consistent with findings reporting the emergence of T-cell tumors in transgenic mice over expressing Gfi1. However, lower levels of GFI1 expression was shown to be a strong indicator for worse prognosis in a group of T-ALL patients, although higher levels would have been expected. To find a solution for this discrepancy, we investigated whether Gfi1 dosage may be important in T-cell leukemogenesis or even in normal T-cell development. We have generated a new strain of knockin mice, which express a human GFI1 gene either at the same level as the endogenous wild type Gfi1 gene (Gfi1KI/KI) or at reduced levels (Gfi1KD/KD). We observed that low-level expression of Gfi1 leads to a reduction of thymocyte numbers (3 fold), and neutropenia in bone marrow and blood (p≤0.01). This correlates well with the phenotype of previously described Gfi1 knockout mice (Gfi1KO/KO). Interestingly however, unlike Gfi1KO/KO mice, Gfi1KD/KD animals showed a normal B-cell development, suggesting that low Gfi1 levels disturb T-cell and myeloid development but are sufficient to support the differentiation of B-cells. Next we induced T-ALL in wt, Gfi1KO/KO or Gfi1KD/KD mice by injecting them with a single dose of N-ethyl-N-Nitroso-urea. About 15 % of wt mice developed T-cell tumors with a median latency of 140 days as was expected. Absence of Gfi1 (Gfi1KO/KO) impeded tumor development with only 5 % of mice developing tumors and this within a longer latency period. In contrast, Gfi1KD/KD mice developed tumors with a higher incidence (57%) and shorter latency period (100 days) than wt or Gfi1KO/KO mice (p≤0.01 for incidence and latency). Also Gfi1KD/KD mice developing a tumor showed a 3 fold higher number of blasts in the peripheral blood that wt mice developing T-cell leukemia (p≤0.01). Both the shorter latency period and the higher number of blasts is indicative of a more aggressive disease course in animals with low levels of Gfi1 expression. Interestingly, not only tumors arising in Gfi1KD/KD showed lower level of Gfi1 expression but also T-ALL cells from ENU treated wt mice exhibited a 4–8 fold lower expression level of Gfi1 than normal non-leukemic wt thymocytes suggesting that Gfi1 is downregulated upon development of leukemia. Evasion of apoptosis is one hallmark of leukemia initiation and thus we studied how the different level of Gfi1 might influence apoptotic answer. We observed that Gfi1KO/KO thymocytes were more sensitive to DNA induced cell death than wt thymocytes and underwent 2–3 times more apoptosis (p≤0.01) after DNA damage induction, which might explain why absence of Gfi1 impedes tumor initiation. In contrast Gfi1KD/KD thymocytes showed a similar rate of apoptosis as wt thymocytes. We conclude that reduced levels of Gfi1 are not sufficient to sustain a fully normal pre-T cell development, but protect against apoptosis. Thus, the differentiation block, which is a prerequisite in any leukemia development, and a protection against apoptosis might accelerate T-cell leukemia development in Gfi1KD/KD mice. This would indicate that the role of Gfi1 in the malignant transformation of T-cell is dose dependent and that low level of Gfi1 expression (but not absence) favors leukemia development and this might be one explanation why lower level of Gfi1 is associated with worse prognosis in T-ALL patients. Disclosures: No relevant conflicts of interest to declare.


Blood ◽  
2012 ◽  
Vol 120 (21) ◽  
pp. 116-116
Author(s):  
Ana Silva ◽  
Joao T. Barata ◽  
Benedict Seddon

Abstract Abstract 116 Interleukin 7 (IL-7) and its receptor, a heterodimer constituted by IL-7Rα (hereafter referred to as IL7R) and γc subunits, are essential for normal T-cell development and homeostasis. While it is known for long that IL7R genetic inactivation leads to severe combined immunodeficiency, only recently we and others have found IL7R gain-of-function mutations in T-cell acute lymphoblastic leukemia (T-ALL). In agreement with an oncogenic role for deregulated IL-7/IL7R signaling, IL-7 transgenic mice develop lymphomas and we have shown that xenotransplant models of human T-ALL rely on microenvironmental IL-7 for tumor acceleration. These studies have highlighted the importance of keeping IL7R-mediated signaling within physiological levels. Indeed, throughout normal T-cell development IL7R expression at the cell surface is tightly controlled and there is correlative evidence, from studies in AKR/J mice, that high IL7R levels in developing thymocytes can promote the development of T-cell leukemia. However, no studies have yet directly evaluated the impact of IL7R on T-cell oncogenesis. In the present study, we used a mouse model in which expression of an IL7R transgene is controlled by a tetracycline responsive promotor (TreIL7R rtTAhuCD2Il7r−/− mice) to analyze the role of IL7R-mediated signaling in T-cell leukemogenesis. Continuous expression of TreIL7R upon doxycycline feeding induced thymus hypertrophy and hyperplasia due to increased size and hyperproliferation of T-cells, which subsequently infiltrated lymph nodes, spleen and bone marrow, ultimately leading to leukemia/lymphoma-associated death. Adoptive transfer of thymic TreIL7R cells to immunodeficient mice confirmed their malignant origin. Surprisingly, tumors developed in recipient animals even in the absence of doxycycline administration, indicating that they eventually become independent of continuous IL7R expression. Remarkably, the tumors mimicked several features of human T-ALL. First, their immunophenotype varied considerably between animals (from CD4 CD8 double-negative to double positive to CD4 or CD8 single positive cells), reflecting the heterogeneity of human disease. Second, similar to the majority of primary T-ALL cases, most tumors displayed hyperactivation of PI3K/Akt pathway, which sometimes associated with absence or decreased PTEN protein expression. Third, the cell cycle inhibitor p27Kip1 was frequently downregulated, a molecular characteristic associated with some T-ALLs. We next sought to determine the contribution of TCR diversity to IL7R-mediated tumorigenesis by crossing mice to the F5 TCR transgenic background. Tumor development in these mice occurred with similar timing and incidence, suggesting that the tumors arise irrespectively of whether a clonal or polyclonal TCR repertoire exists. Finally, the role of Rag recombinase dependent genomic instability in tumor development was assessed by further crossing mice F5 TreIL-7R rtTAhuCD2Il7r−/− mice to Rag1−/− background. Tumor development occurred independently of Rag1 expression, indicating a dominant role for IL7R elicited signals in tumorigenesis. Altogether, our results reveal that continuous IL7R-mediated signaling promotes T-cell tumorigenesis in vivo, providing further indication that IL7R can act as a critical T-cell oncogene. Disclosures: No relevant conflicts of interest to declare.


2016 ◽  
Vol 65 (1) ◽  
pp. 82-87 ◽  
Author(s):  
Haihao Wang ◽  
Qiannan Guo ◽  
Peiwen Yang ◽  
Guoxian Long

Adult T-cell leukemia/lymphoma (ATL) is a highly aggressive T-cell malignancy. This study was designed to explore the expression and functional significance of microRNA (miR)-212 in ATL. The expression of miR-212 in human ATL tissues and cell lines were investigated. Gain-of-function experiments were carried out to determine the roles of miR-212 in cell proliferation, tumorigenesis, cell cycle progression, and apoptosis. We also identified and functionally characterized the target genes of miR-212 in ATL cells. Compared with normal lymph node biopsies, lymphoma samples from ATL patients displayed underexpression of miR-212 (p=0.0032). Consistently, miR-212 was downregulated in human ATL cell lines, compared with normal T lymphocytes. Restoration of miR-212 significantly (p<0.05) inhibited ATL cell proliferation and tumorigenesis in mice. Overexpression of miR-212 led to an accumulation of G0/G1-phase cells and a concomitant reduction of S-phase cells. Moreover, enforced expression of miR-212-induced significant apoptosis in ATL cells. CCND3, which encodes a cell cycle regulator cyclin D3, was identified as a direct target of miR-212 in ATL cells. Rescue experiments with a miR-212-resistant variant of CCND3 demonstrated that overexpression of CCND3 restored cell-cycle progression and attenuated apoptotic response in miR-212-overexpressing ATL cells. Taken together, miR-212 exerts growth-suppressive effects in ATL cells largely by targeting CCND3 and may have therapeutic potential in ATL.


Blood ◽  
2014 ◽  
Vol 124 (21) ◽  
pp. 2214-2214
Author(s):  
Sonia Rodriguez-Rodriguez ◽  
Lin Wang ◽  
Huajia Zhang ◽  
Amy Zollman ◽  
Angelo A. Cardoso ◽  
...  

Abstract Acute Lymphoblastic Leukemia (ALL) is the most common pediatric cancer. Despite the significant clinical successes in the treatment of pediatric T-ALL, leukemia relapse, refractory disease and induction failure (around 30% of patients) remain significant clinical problems, which are often life-threatening. ALL remains the second leading cause of childhood death. Thus, more effective, curative therapeutic strategies are much needed, particularly for refractory and relapse T- ALL. Recent advances in understanding the biology and the molecular alterations of acute lymphoblastic leukemias have led to identification of new molecular targets, such as the Notch signaling pathway. Constitutive activation of Notch signaling is involved in more than 50% of human T-ALL, and overexpression of activated Notch induces T-cell leukemia and lymphoma in murine tumor models. However, disruption of Notch signaling by gamma-secretase inhibitors (GSI) failed to fulfill its clinical promise and, overall, the significant advances attained in dissecting the molecular effectors in T-ALL has yet to translate into effective, curative molecular therapies for relapse patients. Furthermore, despite multiple studies on Notch signaling, little is known on the role of its downstream mediators in T-cell ALL. Previous studies in our laboratory demonstrated that Notch1 activation induces transcriptional activation of SKP2, the F-box protein of the SCF E3-ubiquitin ligase complex. SKP2 is the main F-box protein regulating cell cycle, promoting downregulation of the CKIs (p21Cip1, p27Kip1, p57Kip2 and p130) and its overexpression accelerate cell cycle progression in hematopoietic cells. SKP2 overexpression is frequently associated with cancers, in particular lymphomas and leukemias, and correlates with poor prognosis. We found that Skp2 expression is dynamically regulated during T-cell development coinciding with the Notch expression pattern. Moreover, primary thymocytes cultured in vitro, responded to Notch stimulation by the Delta1 ligand increasing their Skp2 expression and their cell cycle status, whereas the loss of SKP2 impaired their ability to mount a proliferative response to IL-7 stimulation. Importantly, we observed that SKP2 expression is increased in T-ALL patient samples and that mice with Notch-induced T-cell leukemia showed 5 fold upregulation of Skp2 expression. Our hypotheses are that Notch activation promotes T-cell leukemogenesis by altering the cell cycle control through upregulation of Skp2, and that selective targeting of SKP2 is a novel, effective therapeutic strategy for childhood T-ALL. To test whether SKP2 is a key downstream mediator of Notch in T-ALL, we transduced oncogenic Notch (ICN; the constitutive intracellular form) in hematopoietic cells lacking SKP2 from Skp2-/- null mice, and in controls and we determine their ability to induce leukemia in irradiated recipients. Loss of SKP2 significantly delayed the development of T-cell leukemia and increased animal survival by 40%. Taken together, these results demonstrate a previously unrecognized role for SKP2 in the initiation and progression of T-ALL and its potential role as a therapeutic target. Disclosures No relevant conflicts of interest to declare.


PLoS ONE ◽  
2017 ◽  
Vol 12 (2) ◽  
pp. e0171164 ◽  
Author(s):  
Stefan Nagel ◽  
Claudia Pommerenke ◽  
Michaela Scherr ◽  
Corinna Meyer ◽  
Maren Kaufmann ◽  
...  

2015 ◽  
Vol 2015 ◽  
pp. 1-11 ◽  
Author(s):  
Christophe Nicot

Tumor suppressor functions are essential to control cellular proliferation, to activate the apoptosis or senescence pathway to eliminate unwanted cells, to link DNA damage signals to cell cycle arrest checkpoints, to activate appropriate DNA repair pathways, and to prevent the loss of adhesion to inhibit initiation of metastases. Therefore, tumor suppressor genes are indispensable to maintaining genetic and genomic integrity. Consequently, inactivation of tumor suppressors by somatic mutations or epigenetic mechanisms is frequently associated with tumor initiation and development. In contrast, reactivation of tumor suppressor functions can effectively reverse the transformed phenotype and lead to cell cycle arrest or death of cancerous cells and be used as a therapeutic strategy. Adult T-cell leukemia/lymphoma (ATLL) is an aggressive lymphoproliferative disease associated with infection of CD4 T cells by the Human T-cell Leukemia Virus Type 1 (HTLV-I). HTLV-I-associated T-cell transformation is the result of a multistep oncogenic process in which the virus initially induces chronic T-cell proliferation and alters cellular pathways resulting in the accumulation of genetic defects and the deregulated growth of virally infected cells. This review will focus on the current knowledge of the genetic and epigenetic mechanisms regulating the inactivation of tumor suppressors in the pathogenesis of HTLV-I.


1998 ◽  
Vol 18 (6) ◽  
pp. 3620-3632 ◽  
Author(s):  
Christine Neuveut ◽  
Kenneth G. Low ◽  
Frank Maldarelli ◽  
Iris Schmitt ◽  
Franca Majone ◽  
...  

ABSTRACT Human T-cell leukemia virus type 1 is etiologically linked to the development of adult T-cell leukemia and various human neuropathies. The Tax protein of human T-cell leukemia virus type I has been implicated in cellular transformation. Like other oncoproteins, such as Myc, Jun, and Fos, Tax is a transcriptional activator. How it mechanistically dysregulates the cell cycle is unclear. Previously, it was suggested that Tax affects cell-phase transition by forming a direct protein-protein complex with p16INK4a, thereby inactivating an inhibitor of G1-to-S-phase progression. Here we show that, in T cells deleted for p16INK4a, Tax can compel an egress of cells from G0/G1 into S despite the absence of serum. We also show that in undifferentiated myocytes, expression of Tax represses cellular differentiation. In both settings, Tax expression was found to increase cyclin D-cdk activity and to enhance pRb phosphorylation. In T cells, a Tax-associated increase in steady-state E2F2 protein was also documented. In searching for a molecular explanation for these observations, we found that Tax forms a protein-protein complex with cyclin D3, whereas a point-mutated and transcriptionally inert Tax mutant failed to form such a complex. Interestingly, expression of wild-type Tax protein in cells was also correlated with the induction of a novel hyperphosphorylated cyclin D3 protein. Taken together, these findings suggest that Tax might directly influence cyclin D-cdk activity and function, perhaps by a route independent of cdk inhibitors such as p16INK4a.


2018 ◽  
Vol 9 ◽  
Author(s):  
Ana Rosa Pérez ◽  
Alexandre Morrot ◽  
Vinicius Frias Carvalho ◽  
Juliana de Meis ◽  
Wilson Savino

2003 ◽  
Vol 191 (1) ◽  
pp. 119-138 ◽  
Author(s):  
Julie A. Lucas ◽  
Andrew T. Miller ◽  
Luana O. Atherly ◽  
Leslie J. Berg

Sign in / Sign up

Export Citation Format

Share Document